What is your preferred neoadjuvant chemotherapy regimen for muscle invasive bladder cancer, adequate performance status and preserved kidney function?
Answer from: Medical Oncologist at Academic Institution
I agree, to date there is a lack of published randomized phase 3 data to date (though this is ongoing with NCT01812369) Several retrospective analyses such as one by Peyton et al JAMA Oncol 2019 found that neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) pr...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Preferred is clinical trial; except for that, I consider either accelerated (dose dense) MVAC every 2 weeks with G-CSF or gemcitabine/cisplatin (21-day cycle). Relevant data include S8710 phase 3 trial, EORTC-MRC phase 3 trial, meta-analysis, recent S1314 (COXEN trial), Plimack et al. JCO 2014, Chou...
Comments
Medical Oncologist at Stanford School of Medicine
Has recent data from the COXEN (S1314) trial and V...
Has recent data from the COXEN (S1314) trial and V...